Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
News
-
December 5, 2021Shareholder disclosure by Radforsk Investeringsstiftelse
-
December 1, 2021Targovax ASA – Exercise of subscription rights in the rights issue by close associate of a primary insider
-
November 30, 2021Targovax ASA – Exercise of subscription rights in the rights issue by close associate of a primary insider
-
November 30, 2021Targovax ASA – Receipt of subscription rights in the rights issue by primary insiders and their close associates
Q3 Third quarter 2021
Targovax ASA announced its third quarter 2021 results on Thursday November 4, 2021. An online presentation by Targovax’s management to investors, analysts and the press will take place at 10:00 am CET.